Dextromethorphan/Bupropion (Auvelity) for Depression
December 26, 2022 (Issue: 1666)
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
- Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect. Med Lett Drugs Ther 2011; 53:46.
- Drugs for depression. Med Lett Drugs Ther 2020; 62:25.
- A new indication for esketamine nasal spray (Spravato). Med Lett Drugs Ther 2020; 62:151.
- DV Iosifescu et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry 2022; 83:21m14345.
- H Tabuteau et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry 2022; 179:490.
- Axsome Therapeutics, Inc. News Release. Axsome Therapeutics announces topline results of the STRIDE-1 phase 3 trial in treatment resistant depression and expert call to discuss clinical implications. March 30, 2020. Available at: https://bit.ly/3VLIrUP. Accessed December 8, 2022.
- Axsome Therapeutics, Inc. News Release. Axsome Therapeutics announces AXS-05 achieves primary endpoint in the ACCORD phase 3 trial in Alzheimer’s disease agitation. November 28, 2022. Available at: https://bit.ly/3gUHivh. Accessed December 8, 2022.
- M Fornaro et al. The FDA “black box” warning on antidepressant suicide risk in young adults: more harm than benefits? Front Psychiatry 2019; 10:294.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- AF Schatzberg. Understanding the efficacy and mechanism of action of a dextromethorphan-bupropion combination: where does it fit in the NMDA versus mu-opioid story? Am J Psychiatry 2022; 179:448.
- Approximate WAC for 30 days’ treatment at the usual dosage. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. December 5, 2022. Reprinted with permission by First Databank, Inc. All rights reserved. ©2022. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
